References
- CitromeLStensbølTBMaedaKThe preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?Expert Rev Neurother201515101219122926402059
- CorrellCUSkubanAHobartMEfficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studiesSchizophr Res20161741–3829227157799
- Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia (STEP 203)2010 Available from: https://clinicaltrials.gov/ct2/show/NCT00905307. NLM identifier: NCT00905307
- CorrellCUSkubanAOuyangJEfficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled TrialAm J Psychiatry2015172987088025882325
- KaneJMSkubanAOuyangJA multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophreniaSchizophr Res20151641–312713525682550
- KaySROplerLALindenmayerJPThe Positive and Negative Syndrome Scale (PANSS): rationale and standardisationBr J Psychiatry Suppl1989775967
- IshigookaJIwashitaSTadoriYEfficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled studyPsychiatry Clin Neurosci2018
- TakeuchiHFathiAThiyanavadivelSAgidORemingtonGCan Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled TrialsJ Clin Psychiatry2018792
- di SciascioGRivaMAAripiprazole: from pharmacological profile to clinical useNeuropsychiatr Dis Treat2015112635264726508859
- ChouinardGSamahaANChouinardVAAntipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and TherapyPsychother Psychosom201786418921928647739
- MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementBMJ2009339b253519622551
- GuyWBonatoRRManual for the ECDEU Assessment Battery2nd edChevy Chase, MDNational Institute of Mental Health1970
- FleischhackerWWKemmlerGThe clinical relevance of percentage improvements on the PANSS scoreNeuropsychopharmacology200732112435243617940536
- RevManReview Manager (RevMan) [Computer program]. Version 5.3CopenhagenThe Nordic Cochrane Centre, The Cochrane Collaboration2014
- HigginsJGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.10The Cochrane Collaboration2011 Available from: http://handbook.cochrane.orgAccessed March 30, 2011
- EssockSMHargreavesWADohmFAGoetheJCarverLHipshmanLClozapine eligibility among state hospital patientsSchizophr Bull199622115258685657
- NaciHDiasSAdesAEIndustry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statinsBMJ2014349g574125281681